[Pharmacokinetics of PEG recombinant human interleukin-6 in rats].
OBJECTIVE
To study the pharmacokinetics and tissue distribution of PEG-rhIL-6 in rats after a single dose administration.


METHODS
Pharmacokinetics and distribution of PEG-rhIL-6 in rats were studied by 125I isotope tracing method. Pharmacokinetic analysis was performed using 3P97 computer software.


RESULTS
PEG-rhIL-6 declined in one-compartment model with half-lives of 10.44-11.37 h for t1/2 Ka, 19.77-21.53 h for t1/2 Ke and 20.51-21.96 h for T(pcak), respectively. PEG-rhIL-6 was mainly distributed in blood and excreted via urine.


CONCLUSIONS
The half-lives of PEG-rhIL-6 are prolonged after being modified by PEG.
He
Xue-Ling
XL
Laboratory Animal Center, Sichuan University, Chengdu 610041, China.
Yang
Guang
G
Yin
Hai-Lin
HL
Zhang
Xue-Me
XM
D000818:Animals; D005260:Female; D006207:Half-Life; D006801:Humans; D007279:Injections, Subcutaneous; D015850:Interleukin-6 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014018:Tissue Distribution
C508600:IL6 protein, human; D015850:Interleukin-6; D011994:Recombinant Proteins; D011092:Polyethylene Glycols